DE LAURENTIIS, MICHELINO
DE LAURENTIIS, MICHELINO
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA
Targeted Therapy of Breast Cancer
2009 DE LAURENTIIS, Michelino; Zielinski, C.
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part
2007 G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino
CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).
1995 DE PLACIDO, Sabino; F., Perrone; Carlomagno, Chiara; A., Morabito; Pagliarulo, Clorindo; Lauria, Rossella; Marinelli, Alfredo; DE LAURENTIIS, Michelino; E., Varriale; Petrella, Giuseppe
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer.
1993 A. R., Bianco; DE PLACIDO, Sabino; F., Perrone; Carlomagno, Chiara; DE LAURENTIIS, Michelino; L., Del Mastro; R., Lauria; Marinelli, Alfredo; C., Gallo
A Metanalysis on the Interaction between HER2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer
2005 DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, E; Ruggiero, A; Carlomagno, Chiara; Ciardiello, F; Tortora, G; D’Agostino, D; Caputo, F; Cancello, G; Montagna, E; Malorni, L; Zinno, L; Lauria, R; Bianco, Ar; DE PLACIDO, Sabino
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.
2002 Carlomagno, Chiara; Lauria, Rossella; DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, Erminia; Ferrara, Claudia; Milano, Andrea; Vernaglia, LOMBARDI ALESSANDRA; Costanzo, Raffaele; G., Catalano; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino
SECOND-LINE CHEMOTHERAPY WITH A HYBRID-ALTERNATING REGIMEN OF BOLUS FLUOROURACIL MODULATED BY METHOTREXATE AND INFUSIONAL FLUOROURACIL MODULATED BY FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL CANCERPRETREATED WITH FLUOROURACIL. A PHASE II STUDY.
2002 Carlomagno, C; DE LAURENTIIS, Michelino; Lauria, R; Arpino, Grazia; Massarelli, E; Ferrara, C; Milano, A; VERNAGLIA LOMBARDI, A; Costanzo, R; Catalano, G; Bianco, Ar; DE PLACIDO, Sabino
Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy.
2011 Harbeck, N; Ewer, Ms; DE LAURENTIIS, Michelino; Suter, Tm; Ewer, Sm
IS THERE A STANDARD CHEMOTHERAPEUTIC REGIMEN FOR HORMONE-REFRACTORY PROSTATE CANCER? PRESENT AND FUTURE APPROACHES IN THE MANAGEMENT OF THE DISEASE.
2003 DI LORENZO, G; Autorino, R; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, R; Giordano, A; DE SIO, M; Darmiento, M; Bianco, Ar; DE PLACIDO, Sabino
NUCLEAR DNA CONTENT-DERIVED PARAMETERS CORRELATED WITH HETEROGENEOUS EXPRESSION PF P53 AND BCL-2 PROTEINS IN CLEAR CELL RENAL CARCINOMA
2000 Pepe, S; Ruggiero, A; D'Acquisto, M; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.
2011 Giuliano, Mario; Giordano, A; Jackson, S; Hess, Kr; De Giorgi, U; Mego, M; Handy, Bc; Ueno, Nt; Alvarez, Rh; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Valero, V; Hortobagyi, Gn; Reuben, Jm; Cristofanilli, M.
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up.
1999 DE PLACIDO, Sabino; Carlomagno, Chiara; Ciardiello, F; DE LAURENTIIS, Michelino; Pepe, Stefano; Ruggiero, A; Tortora, Giampaolo; Panico, L; D’ ANTONIO, A; Pettinato, Guido; Petrella, Giuseppe; Bianco, Ar
EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CORRELATES WITH DISEASE RELAPSE AND PROGRESSION TO ANDROGEN-INDEPEDENCE IN HUMAN PROSTATE CANCER.
2002 DI LORENZO, G; Tortora, G; D'Armiento, FRANCESCO PAOLO; DE ROSA, G; Staibano, Stefania; Autorino, R; D'Armiento, Maria; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Catalano, G; Bianco, Ar; Ciardiello, F.
Survival Analysis by means of a novel Neural Network Model
2003 Eleuteri, A; Tagliaferri, R; DE PLACIDO, Sabino; DE LAURENTIIS, Michelino
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's Lymphoma patients non-elegible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination.
1995 P., Tagliaferri; Matano, Elide; A., Rea; M., Famiani; F., Ciardiello; G., Tortora; V., Montesarchio; A., Morabito; M., Caraglia; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Palmieri, Giovannella; A. R., Bianco
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
2005 Howell, A; Cuzick, J; Baum, M; Buzdar, A; Dowsett, M; Forbes, Jf; Hoctin Boes, G; Houghton, J; Locker, Gy; Tobias, Js; ATAC Trialists', Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Carlomagno, Chiara
The prognostic value of lymphatic and blood vessel invasion in operable breast cancer.
1995 Lauria, R.; Perrone, F.; Carlomagno, Chiara; DE LAURENTIIS, Michelino; Morabito, A.; Gallo, C.; Varriale, E.; Pettinato, Guido; Panico, L.; Petrella, G.; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up.
1999 DE PLACIDO, Sabino; Carlomagno, C.; Ciardiello, F.; DE LAURENTIIS, Michelino; Pepe, S.; Ruggiero, A.; Tortora, G.; Panico, L.; D'Antonio, A.; Pettinato, G.; Petrella, G.; Bianco, A. R.
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.
2005 DE PLACIDO, Sabino; DE LAURENTIIS, Michelino; DE LENA, M; Lorusso, V; Paradiso, A; D'Aprile, M; Pistillucci, G; Farris, A; Sarobba, Mg; Palazzo, S; Manzione, L; Adamo, V; Palmeri, S; Ferrau, F; Lauria, Rossella; Pagliarulo, C; Petrella, Giuseppe; Limite, Gennaro; Costanzo, Raffaele; Bianco, Ar; GOCSI COOPERATIVE, G. R. O. U. P.
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.
2003 DE PLACIDO, Sabino; DE LAURENTIIS, Michelino; Carlomagno, C; Gallo, C; Perrone, F; Pepe, S; Ruggiero, A; Marinelli, Alfredo; Pagliarulo, C; Panico, L; Pettinato, ; Petrella, G; Bianco, Ar
Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
---|---|---|---|---|
Targeted Therapy of Breast Cancer | 8.01 Chairman di Sessioni di Convegni Internazionali | 2009 | DE LAURENTIIS, Michelino; Zielinski, C. | |
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part | 1.5 Abstract in rivista | 2007 | G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino | |
CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). | 1.1 Articolo in rivista | 1995 | DE PLACIDO, Sabino; F., Perrone; Carlomagno, Chiara; A., Morabito; Pagliarulo, Clorindo; Lauria, Rossella; Marinelli, Alfredo; DE LAURENTIIS, Michelino; E., Varriale; Petrella, Giuseppe | |
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer. | 1.1 Articolo in rivista | 1993 | A. R., Bianco; DE PLACIDO, Sabino; F., Perrone; Carlomagno, Chiara; DE LAURENTIIS, Michelino; L., Del Mastro; R., Lauria; Marinelli, Alfredo; C., Gallo | |
A Metanalysis on the Interaction between HER2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer | 1.1 Articolo in rivista | 2005 | DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, E; Ruggiero, A; Carlomagno, Chiara; Ciardiello, F; Tortora, G; D’Agostino, D; Caputo, F; Cancello, G; Montagna, E; Malorni, L; Zinno, L; Lauria, R; Bianco, Ar; DE PLACIDO, Sabino | |
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. | 1.1 Articolo in rivista | 2002 | Carlomagno, Chiara; Lauria, Rossella; DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, Erminia; Ferrara, Claudia; Milano, Andrea; Vernaglia, LOMBARDI ALESSANDRA; Costanzo, Raffaele; G., Catalano; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino | |
SECOND-LINE CHEMOTHERAPY WITH A HYBRID-ALTERNATING REGIMEN OF BOLUS FLUOROURACIL MODULATED BY METHOTREXATE AND INFUSIONAL FLUOROURACIL MODULATED BY FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL CANCERPRETREATED WITH FLUOROURACIL. A PHASE II STUDY. | 2.1 Contributo in volume (Capitolo o Saggio) | 2002 | Carlomagno, C; DE LAURENTIIS, Michelino; Lauria, R; Arpino, Grazia; Massarelli, E; Ferrara, C; Milano, A; VERNAGLIA LOMBARDI, A; Costanzo, R; Catalano, G; Bianco, Ar; DE PLACIDO, Sabino | |
Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. | 1.1 Articolo in rivista | 2011 | Harbeck, N; Ewer, Ms; DE LAURENTIIS, Michelino; Suter, Tm; Ewer, Sm | |
IS THERE A STANDARD CHEMOTHERAPEUTIC REGIMEN FOR HORMONE-REFRACTORY PROSTATE CANCER? PRESENT AND FUTURE APPROACHES IN THE MANAGEMENT OF THE DISEASE. | 2.1 Contributo in volume (Capitolo o Saggio) | 2003 | DI LORENZO, G; Autorino, R; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, R; Giordano, A; DE SIO, M; Darmiento, M; Bianco, Ar; DE PLACIDO, Sabino | |
NUCLEAR DNA CONTENT-DERIVED PARAMETERS CORRELATED WITH HETEROGENEOUS EXPRESSION PF P53 AND BCL-2 PROTEINS IN CLEAR CELL RENAL CARCINOMA | 1.1 Articolo in rivista | 2000 | Pepe, S; Ruggiero, A; D'Acquisto, M; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino | |
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. | 1.1 Articolo in rivista | 2011 | Giuliano, Mario; Giordano, A; Jackson, S; Hess, Kr; De Giorgi, U; Mego, M; Handy, Bc; Ueno, Nt; Alvarez, Rh; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Valero, V; Hortobagyi, Gn; Reuben, Jm; Cristofanilli, M. | |
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up. | 1.1 Articolo in rivista | 1999 | DE PLACIDO, Sabino; Carlomagno, Chiara; Ciardiello, F; DE LAURENTIIS, Michelino; Pepe, Stefano; Ruggiero, A; Tortora, Giampaolo; Panico, L; D’ ANTONIO, A; Pettinato, Guido; Petrella, Giuseppe; Bianco, Ar | |
EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CORRELATES WITH DISEASE RELAPSE AND PROGRESSION TO ANDROGEN-INDEPEDENCE IN HUMAN PROSTATE CANCER. | 1.1 Articolo in rivista | 2002 | DI LORENZO, G; Tortora, G; D'Armiento, FRANCESCO PAOLO; DE ROSA, G; Staibano, Stefania; Autorino, R; D'Armiento, Maria; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Catalano, G; Bianco, Ar; Ciardiello, F. | |
Survival Analysis by means of a novel Neural Network Model | 1.1 Articolo in rivista | 2003 | Eleuteri, A; Tagliaferri, R; DE PLACIDO, Sabino; DE LAURENTIIS, Michelino | |
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's Lymphoma patients non-elegible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination. | 1.1 Articolo in rivista | 1995 | P., Tagliaferri; Matano, Elide; A., Rea; M., Famiani; F., Ciardiello; G., Tortora; V., Montesarchio; A., Morabito; M., Caraglia; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Palmieri, Giovannella; A. R., Bianco | |
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. | 1.1 Articolo in rivista | 2005 | Howell, A; Cuzick, J; Baum, M; Buzdar, A; Dowsett, M; Forbes, Jf; Hoctin Boes, G; Houghton, J; Locker, Gy; Tobias, Js; ATAC Trialists', Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Carlomagno, Chiara | |
The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. | 1.1 Articolo in rivista | 1995 | Lauria, R.; Perrone, F.; Carlomagno, Chiara; DE LAURENTIIS, Michelino; Morabito, A.; Gallo, C.; Varriale, E.; Pettinato, Guido; Panico, L.; Petrella, G.; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino | |
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up. | 1.1 Articolo in rivista | 1999 | DE PLACIDO, Sabino; Carlomagno, C.; Ciardiello, F.; DE LAURENTIIS, Michelino; Pepe, S.; Ruggiero, A.; Tortora, G.; Panico, L.; D'Antonio, A.; Pettinato, G.; Petrella, G.; Bianco, A. R. | |
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. | 1.1 Articolo in rivista | 2005 | DE PLACIDO, Sabino; DE LAURENTIIS, Michelino; DE LENA, M; Lorusso, V; Paradiso, A; D'Aprile, M; Pistillucci, G; Farris, A; Sarobba, Mg; Palazzo, S; Manzione, L; Adamo, V; Palmeri, S; Ferrau, F; Lauria, Rossella; Pagliarulo, C; Petrella, Giuseppe; Limite, Gennaro; Costanzo, Raffaele; Bianco, Ar; GOCSI COOPERATIVE, G. R. O. U. P. | |
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. | 1.1 Articolo in rivista | 2003 | DE PLACIDO, Sabino; DE LAURENTIIS, Michelino; Carlomagno, C; Gallo, C; Perrone, F; Pepe, S; Ruggiero, A; Marinelli, Alfredo; Pagliarulo, C; Panico, L; Pettinato, ; Petrella, G; Bianco, Ar |